Hims stock jumps 50% as Novo Nordisk ends lawsuit, strikes deal
Telehealth platforms are becoming a gateway for access to blockbuster weight loss medicines. That shift became clearer on Monday after Novo Nordisk dropped its patent infringement lawsuit against digital health provider Hims & Hers. The Danish pharmaceutical company has instead agreed to allow Hims to distribute its branded semaglutide drugs through its telehealth platform. The
